J&J shells out $1.75bn for viral therapies developer Alios
Johnson & Johnson is buying private infectious disease therapeutics developer Alios BioPharma Inc. for $1.75bn in cash.
- Large Molecule
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.